KemPharm, Inc. announced that Richard W. Pascoe, who has been serving as Executive Chairman, will transition into the role of Chief Executive Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.85 USD | -4.26% | +37.32% | -10.69% |
Jul. 01 | Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to Russell 3000 Growth Index | CI |
Jul. 01 | Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to Russell Microcap Growth Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.69% | 245M | |
+7.04% | 73.13B | |
+31.10% | 10.38B | |
+37.94% | 5.16B | |
-17.33% | 4.73B | |
+21.49% | 3.81B | |
+24.92% | 2.26B | |
-36.84% | 1.88B | |
-43.31% | 1.77B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- ZVRA Stock
- News Zevra Therapeutics, Inc.
- KemPharm, Inc. Appoints Richard W. Pascoe, as Chief Executive Officer